Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)
Risk Analysis, Volume 33, No. 4, Year 2013
Notification
URL copied to clipboard!
Description
The live, attenuated oral poliovirus vaccine (OPV) provides a powerful tool for controlling and stopping the transmission of wild polioviruses (WPVs), although the risks of vaccine-associated paralytic polio (VAPP) and circulating vaccine-derived poliovirus (cVDPV) outbreaks exist as long as OPV remains in use. Understanding the dynamics of cVDPV emergence and outbreaks as a function of population immunity and other risk factors may help to improve risk management and the development of strategies to respond to possible outbreaks. We performed a comprehensive review of the literature related to the process of OPV evolution and information available from actual experiences with cVDPV outbreaks. Only a relatively small fraction of poliovirus infections cause symptoms, which makes direct observation of the trajectory of OPV evolution within a population impractical and leads to significant uncertainty. Despite a large global surveillance system, the existing genetic sequence data largely provide information about transmitted virulent polioviruses that caused acute flaccid paralysis, and essentially no data track the changes that occur in OPV sequences as the viruses transmit largely asymptomatically through real populations with suboptimal immunity. We updated estimates of cVDPV risks based on actual experiences and identified the many limitations in the existing data on poliovirus transmission and immunity and OPV virus evolution that complicate modeling. Modelers should explore the space of potential model formulations and inputs consistent with the available evidence and future studies should seek to improve our understanding of the OPV virus evolution process to provide better information for policymakers working to manage cVDPV risks. © 2013 Society for Risk Analysis.
Authors & Co-Authors
Pallansch, Mark A.
United States, Atlanta
Centers for Disease Control and Prevention
Kim, Jong-hoon
United States, Orlando
Kid Risk, Inc.
Burns, Cara Carthel
United States, Atlanta
Centers for Disease Control and Prevention
Kew, Olen M.
United States, Atlanta
Centers for Disease Control and Prevention
Oberste, Mark Steven
United States, Atlanta
Centers for Disease Control and Prevention
Diop, Ousmane Madiagne
Switzerland, Geneva
Organisation Mondiale de la Santé
Wassilak, Steven G.Fite
United States, Atlanta
Centers for Disease Control and Prevention
Cochi, Stephen L.
United States, Atlanta
Centers for Disease Control and Prevention
Thompson, Kimberly M.
United States, Orlando
Kid Risk, Inc.
United States, Orlando
University of Central Florida
Statistics
Citations: 87
Authors: 9
Affiliations: 4
Identifiers
Doi:
10.1111/risa.12022
ISSN:
15396924
Research Areas
Genetics And Genomics
Health System And Policy
Study Design
Cross Sectional Study